查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566975

Diferiprone 市場：依形式、應用、通路分類：2024-2033 年全球機會分析與產業預測

Deferiprone Market By Form , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

去甲酮市場

2023 年，diferiprone 市值為 3,340 萬美元，預計 2024 年至 2033 年複合年成長率為 3.2%，到 2033 年達到 4,590 萬美元。

去鐵酮是一種化合物，用作治療由輸血和重型地中海貧血引起的鐵超負荷的藥物。 Diferiprone 的作用是螯合鐵並透過尿液將其從血液中清除。去鐵酮以錠劑或口服溶液形式服用，容易在上胃腸道吸收。

去鐵酮市場的成長主要是由於需要定期輸血的疾病（例如地中海貧血和鐮狀性貧血）的盛行率不斷上升所推動的。此外，人們對鐵失調的認知不斷提高，正在推動去鐵酮用於治療鐵超負荷的應用。此外，一些政府致力於提高治療慢性疾病和鐵相關疾病的能力，這推動了對去鐵酮的需求。這有利於市場的開拓。目前，市場上有擴大去鐵酮使用範圍的趨勢。根據美國癌症研究協會期刊上發表的報導，去鐵酮有望作為控制轉移性卵巢癌的替代免疫療法藥物。

然而，去鐵酮的不當給藥或過量會導致嚴重的副作用，例如粒細胞缺乏症和嗜中性白血球低下症，限制了其效用並阻礙了市場成長。此外，該藥物還面臨來自同等有效的替代品（如去鐵胺和地拉羅司）的激烈競爭。這極大地限制了去鐵酮市場的開拓。相較之下，個人化醫療的日益普及預計將為市場帶來新的途徑。個人化醫療是指提供適合個人健康和身體狀況的藥物和治療。客製化劑量預計將推動去鐵酮的廣泛使用，因為它對人類造成副作用的可能性很小。

按部門審查

去鐵酮市場分為形式、應用、分銷管道和地區。按形式分類，市場分為錠劑和其他。依用途可分為輸血引起的鐵超載病和NTDT引起的鐵超負荷病。依分銷通路分類，可分為醫院藥局、藥局/零售藥局及網路供應商。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按格式分類，錠劑細分市場將在 2023 年佔據主導地位。

從應用來看，預計到 2033 年，輸血鐵超載細分市場將佔據較高的市場佔有率。

按分銷管道分類，線上提供者部門預計將成為整個預測期內的最大股東。

按地區分類，2023 年北美市場收益最高。

可以使用此報告進行客製化（需要額外費用和時間表）

  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章去鐵酮市場：依形式

  • 市場概況
  • 錠劑
  • 其他

第5章去鐵酮市場：依應用分類

  • 市場概況
  • 輸血鐵超負荷
  • NTDT 引起的鐵過載

第6章去鐵酮市場：按分銷管道

  • 市場概況
  • 醫院藥房
  • 藥局
  • 線上提供者

第7章去鐵酮市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國diferiprone市場
    • 加拿大diferiprone市場
    • 墨西哥 Diferiprone 市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國Differiprone市場
    • 德國迪非普隆市場
    • 義大利迪非普隆市場
    • 西班牙 Diferiprone 市場
    • 英國迪非普隆市場
    • 其他歐洲迪非普酮市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國異丙酮市場
    • 日本diferiprone市場
    • 印度迪非普隆市場
    • 韓國diferiprone市場
    • 澳洲diferiprone市場
    • 其他亞太地區迪非酮市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西 Diferiprone 市場
    • 南非 Diferiprone 市場
    • 沙烏地阿拉伯 Diferiprone 市場
    • 拉丁美洲、中東和非洲的迪非普隆其他市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Apotex Inc
  • Cipla Limited
  • VHB Life Sciences Limited
  • Taro Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Chiesi Farmaceutici SpA
  • Zydus Cadila
  • Cipla Inc.
  • Pfizer
簡介目錄
Product Code: A324401

Deferiprone Market

The deferiprone market was valued at $33.4 million in 2023 and is projected to reach $45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.

Deferiprone is a compound used as a medication for curing iron overload caused by blood transfusions or thalassemia major. The role of deferiprone involves the chelation of iron and its removal from the bloodstream through urine. Deferiprone is consumed as a tablet or oral solution and is readily absorbed by the upper gastrointestinal tract.

The growth of the deferiprone market is significantly driven by increase in the prevalence of diseases that require regular blood transfusions such as thalassemia and sickle cell anemia. In addition, rise in awareness regarding iron disorders is boosting the adoption of deferiprone for iron overload cases. Furthermore, governments in several countries are focusing on the improvement of treatment capabilities for chronic diseases and iron-related disorders, which is upsurging the demand for deferiprone. This is propelling the development of the market. Currently, explorations regarding expansion of the applications of deferiprone are trending in the market. According to an article posted on the American Association for Cancer Research Journals, deferiprone is anticipated to act as an alternative immunotherapeutic drug for the control of metastatic ovarian cancer.

However, improper or excessive dosage of deferiprone leads to severe side effects such as agranulocytosis and neutropenia, limiting its utility and hampering the growth of the market. Furthermore, the medication faces stringent competition from equally efficient alternatives such as desferrioxamine and deferasirox. This restrains the development of the deferiprone market considerably. Contrarily, rise in the popularity of personalized medicine is projected to present new avenues for the market. Personalized medicine involves providing medications and treatments specifically according to an individual's health and body condition. This is projected to boost the uptake of deferiprone as tailored dosages have minimum to no possibility of causing side effects to the human body.

Segment Review

The deferiprone market is segmented into form, application, distribution channel, and region. On the basis of form, the market is bifurcated into tablets and others. As per application, it is divided into transfusional iron overload and NTDT caused overload. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023.

As per application, the transfusional iron overload segment is anticipated to account for a high market share by 2033.

Depending on distribution channel, the online providers segment is projected to be the highest shareholder throughout the forecast period.

Region wise, North America was the highest revenue generator in the market in 2023.

Competition Analysis

The key players operating in the global deferiprone market include Apotex Inc, Cipla Limited, VHB Life Sciences Limited, Taro Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG, Chiesi Farmaceutici S.p.A, Zydus Cadila, Cipla Inc., and Pfizer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Form

  • Tablets
  • Others

By Application

  • Transfusional Iron Overload
  • NTDT Caused Overload.

By Distribution Channel

  • Hospital Pharmacies
  • Drug store retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Apotex Inc
    • Cipla Limited
    • VHB Life Sciences Limited
    • Taro Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis International AG
    • Chiesi Farmaceutici S.p.A
    • Zydus Cadila
    • Cipla Inc.
    • Pfizer

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: DEFERIPRONE MARKET, BY FORM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Form
  • 4.2. Tablets
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Others
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: DEFERIPRONE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Transfusional Iron Overload
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. NTDT Caused Overload.
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Drug Store Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Providers
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: DEFERIPRONE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Form
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Deferiprone Market
      • 7.2.6.1. Market Size and Forecast, By Form
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Deferiprone Market
      • 7.2.7.1. Market Size and Forecast, By Form
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Deferiprone Market
      • 7.2.8.1. Market Size and Forecast, By Form
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Form
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Deferiprone Market
      • 7.3.6.1. Market Size and Forecast, By Form
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Deferiprone Market
      • 7.3.7.1. Market Size and Forecast, By Form
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Deferiprone Market
      • 7.3.8.1. Market Size and Forecast, By Form
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Deferiprone Market
      • 7.3.9.1. Market Size and Forecast, By Form
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Deferiprone Market
      • 7.3.10.1. Market Size and Forecast, By Form
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Deferiprone Market
      • 7.3.11.1. Market Size and Forecast, By Form
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Form
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Deferiprone Market
      • 7.4.6.1. Market Size and Forecast, By Form
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Deferiprone Market
      • 7.4.7.1. Market Size and Forecast, By Form
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Deferiprone Market
      • 7.4.8.1. Market Size and Forecast, By Form
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Deferiprone Market
      • 7.4.9.1. Market Size and Forecast, By Form
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Deferiprone Market
      • 7.4.10.1. Market Size and Forecast, By Form
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Deferiprone Market
      • 7.4.11.1. Market Size and Forecast, By Form
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Form
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Deferiprone Market
      • 7.5.6.1. Market Size and Forecast, By Form
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Deferiprone Market
      • 7.5.7.1. Market Size and Forecast, By Form
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Deferiprone Market
      • 7.5.8.1. Market Size and Forecast, By Form
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Deferiprone Market
      • 7.5.9.1. Market Size and Forecast, By Form
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Apotex Inc
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Cipla Limited
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. VHB Life Sciences Limited
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Taro Pharmaceutical Industries Ltd.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Sun Pharmaceutical Industries Ltd.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Novartis International AG
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Chiesi Farmaceutici S.p.A
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Zydus Cadila
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Cipla Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments